Optimer Pharmaceuticals, Inc. (NASDAQ: OPTR) announced today that the U.S. Food and Drug Administration (FDA) has approved the company’s antibacterial drug DIFICID™ (fidaxomicin) tablets for the treatment of Clostridium difficile-associated diarrhea (CDAD) in adults 18 years of age and older. CDAD is a significant medical problem in hospitals and long-term care facilities, and is beginning to emerge in the community among people previously at low risk for the disease. In the largest Phase 3 clinical studies ever conducted in CDAD, DIFICID had clinical response rates at the end of treatment that were non-inferior to oral vancomycin. DIFICID was superior to vancomycin in sustaining clinical response through 25 days beyond the end of treatment. DIFICID is the only FDA-approved antibacterial drug proven to be superior to vancomycin in sustained clinical response for CDAD.
To view Multimedia News Release, go to http://multivu.prnewswire.com/mnr/optimerpharma/50177/
Citing projections that by 2030, America’s senior population will reach 20 percent of the population – 78 million people – and new survey information showing that Americans feel increasingly helpless about their personal cancer risk as they grow older, the American Institute for Cancer Research (AICR) today highlighted the emerging research showing that even in later life, many cancers can be delayed or prevented through regular physical activity and a plant-based diet.
To view Multimedia News Release, go to http://multivu.prnewswire.com/mnr/aicr/46620/
She had no idea her fate was sealed. Her destiny chosen. Her abilities could save them all, or cost her her life. But first, she had to survive him. Imprisoned in a volcano with an enemy like no other he was about to be set free. Now, possessed by a being older than himself, he was something else now. More than a Carpathian. Their lives are destined to be together if they can survive the Dark Storm. Dark Storm by Christine Feehan find out more at http://www.christinefeehan.com romance/fantasy
Raptor Pharmaceutical Corp. (“Raptor” or the “Company”) (Nasdaq: RPTP), today announced that the U.S. Food and Drug Administration (FDA) has approved PROCYSBI™ (cysteamine bitartrate) delayed release capsules for the treatment of nephropathic cystinosis in adults and children 6 years and older. In a Phase 3 study, PROCYSBI showed consistent cystine depletion over the full 12-hour dosing period. Sustained levels of cysteamine have not historically been achieved in the majority of patients in this population. Studies have shown that sustained cystine depletion in patients may significantly delay disease progression, including kidney dysfunction, dialysis, kidney transplant, organ failure and premature death.
To view Multimedia News Release, go to http://www.multivu.com/mnr/61338-raptor-pharmaceutical-procysbi-fda-approval-nephropathic-cystinosis
CVS/pharmacy and MinuteClinic announced their “You vs. Flu” campaign today. Flu vaccinations are now available at all CVS/pharmacy and MinuteClinic locations nationwide to help consumers win against the flu. CVS/pharmacy has more than 7,200 locations and MinuteClinic has nearly 600 locations inside select CVS/pharmacy stores.
Flu shots are being provided by CVS pharmacists and MinuteClinic nurse practitioners and physician assistants every day, including evenings and weekends, with no appointment necessary. The Centers for Disease Control and Prevention (CDC) recommends that everyone ages six months and older get a flu shot as soon as vaccine is available, including those who were vaccinated last flu season.
To view Multimedia News Release, go to http://www.multivu.com/mnr/51328-cvs-minuteclinic-flu-shot
Computerized tomographic (CT) colonography (CTC), also known as virtual colonoscopy, is comparable to standard colonoscopy in its ability to accurately detect cancer and precancerous polyps in people ages 65 and older, according to a paper published online today in Radiology. This is consistent with results of the ACRIN National CT Colonography Trial, published in the New England Journal of Medicine in 2008, which demonstrated that CT colonography can serve as a primary colorectal cancer screening option for adults ages 50 and older, but did not specifically break out data for participants ages 65 and older included in the overall analysis. The Centers for Medicare and Medicaid Services have deferred coverage for CT colonography, primarily citing a lack of data on the exam’s performance in Medicare-eligible recipients ages 65 and older.
To view Multimedia News Release, go to http://www.multivu.com/mnr/54777-acrin-national-ct-colonography-study-radiology-cancer-screening-seniors
More than eight in 10 Americans ages 50-64 believe healthy teeth and gums are essential to maintaining overall good health, yet only a third say they are taking good care of their oral health, according to a survey conducted by the American Dental Association (ADA), with Crest® and Oral-B®. To help bridge this gap, Crest Pro-Health and actress, author, and health advocate Marilu Henner are committed to educating older adults about the importance of gum health during the 2nd annual National Gingivitis Awareness Month this September.
To view Multimedia News Release, go to http://multivu.prnewswire.com/mnr/crestprohealth/49093/
To help combat an increasing trend in festive isolation, charity Abbeyfield today launches a nationwide campaign, Companionship At Christmas, to create an alternative to spending the celebratory period alone. The charity is offering free overnight stays and delicious Christmas lunches over the festive season (24th December – 4th January) in over 100 Abbeyfield sheltered houses and care homes. The Charity will take enquiries from now until December via their website or via their dedicated telephone number 0845 052 3553 up until the 18th December.
To view Multimedia News Release, go to http://www.multivu.com/mnr/58633-abbeyfield-launches-companionship-at-christmas-campaign
Exact Sciences Corp. (NASDAQ: EXAS) announced today that the U.S. Food and Drug Administration (FDA) has approved Cologuard, the company’s noninvasive, stool DNA colorectal cancer screening test. Cologuard is the first noninvasive screening test for colorectal cancer that analyzes both stool DNA and blood biomarkers and has been proven to find 92 percent of cancers and 69 percent of the most advanced precancerous polyps in average risk patients. Cologuard, which is available through healthcare providers, offers people 50 and older at average risk for colorectal cancer an easy–to–use screening test they can do in the privacy of their own home.
To view the Multimedia News Release, go to http://www.multivu.com/players/English/7092251-fda-approve-s-exact-sciences-cologuard-screening-test-colorectal-cancer/
http://www.osv.ltd.uk/citroen.php
Based on the C4, the Citroen DS4 is a light, more compact edition that
gives the driver the command of the road. It’s slightly taller than its
“older sibling” by 40mm but 60mm shorter and 20mm wider, spotting a
flexible slanting rear beam, giving it the stability that is buoyed by
a front suspension typical of a MacPherson and a hydraulic power
steering...See More http://www.osv.ltd.uk/citroen.php
Studies show that more than two-thirds of aesthetically-oriented consumers are bothered by submental fullness, or “double chin.” And with social media profile images becoming more important than ever, there is interest in looking one’s best.
Submental fullness due to fat beneath the chin can impact a broad range of both men and women and because the condition can be genetic and resistant to diet and exercise. But there’s KYBELLA®, the first and only FDA-approved injectable treatment that is available by prescription only, that has been proven to improve the appearance of moderate to severe fat beneath the chin by physically destroying fat cells in the treatment area. In two pivotal clinical studies for KYBELLA®, reductions in submental fat volume were observed more frequently in the KYBELLA® treated group of 514 patients compared to the placebo group (508 patients) as measured by both clinician and patient ratings. In addition, visual and emotional impacts of submental fat (happy, bothered, self-conscious, embarrassed, looking older or overweight) were evaluated using a 6-question survey and 79% of 1 and 2-grade composite responders reported satisfaction after 12 weeks post final treatment compared with 33.6% of patients who received placebo.
To view the multimedia release go to:
http://www.multivu.com/players/English/7962051-kybella-injectable-double-chin-treatment-campaign/
Hamas puppet show: Islamic child kills George Bush Aqsa TV (Hamas), Mar. 30, 2008 Bush: Who are you, what brings you here to my home? Child: My daddy, you killed him in the Iraq war. And mommy, you killed her with the criminal Zionists, in Lebanon. My younger and older brothers, you killed them also, with the criminal Zionists, in Gaza's Holocaust. I am orphan, I am orphan, you criminal! Bush, I must take my rights with the sword of Islam. Bush: I repent, just don't kill me. Where are my guards? Guards! Child: (Laughing) There are no guards, and your people surrendered, oh Bush. I'm coming with billions of children from Palestine, Iraq, children from Syria, Lebanon and Afghanistan. Bush: I will give you whatever you want. Come with me to the White House, you and your friends. Child: (Laughing) Bush, you are impure, and it won't help you to go to the White House. It turned into a big mosque for the Islamic nation and Muslims. I will kill you, Bush. It is your fate. I will kill you. (Stabbing Bush) I killed him.
(more)
